Cytek Biosciences, Inc. (CTKB)
| Market Cap | 608.32M +16.9% |
| Revenue (ttm) | 206.71M +5.4% |
| Net Income | -80.58M |
| EPS | -0.63 |
| Shares Out | 129.98M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 795,634 |
| Open | 4.620 |
| Previous Close | 4.620 |
| Day's Range | 4.480 - 4.710 |
| 52-Week Range | 3.280 - 6.180 |
| Beta | 1.17 |
| Analysts | Buy |
| Price Target | 5.56 (+18.8%) |
| Earnings Date | Aug 5, 2026 |
About CTKB
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. The company offers Cytek aurora, northern lights systems, and Cytek aurora evo systems delivers cell analysis; Cytek Aurora CS System, a cellular complexity to perform additional downstream genomic and proteomic studies using phenotyping approaches; enhanced small particle detection; Cytek amnis imagestream imaging flow cytometers; Cytek guava muse cell analyzers; Cytek mu... [Read more]
Financial Performance
In 2025, Cytek Biosciences's revenue was $201.49 million, an increase of 0.52% compared to the previous year's $200.45 million. Losses were -$66.54 million, 1005.3% more than in 2024.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for CTKB stock is "Buy." The 12-month stock price target is $5.56, which is an increase of 18.80% from the latest price.
News
Jury Finds in Cytek's Favor on Three of Four Asserted Claims; Company to Challenge Remaining Finding
FREMONT, Calif., Aug. 21, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences,” “Cytek,” or the “Company”) (Nasdaq: CTKB), a leading cell analysis solutions company, today announced t...
Cytek Biosciences price target lowered to $5 from $5.50 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Cytek Biosciences (CTKB) to $5 from $5.50 and keeps an Equal Weight rating on the shares.
Cytek Biosciences reports Q2 EPS (9c), consensus (2c)
Reports Q2 revenue $48.14M, consensus $48.61M. “Our second quarter results reflect continued execution against our strategic priorities, exemplified by strong double-digit revenue growth in instrument...
Cytek Biosciences sees FY26 revenue $207M-$212M, consensus $208.83M
The company said, “Cytek Biosciences (CTKB) is updating its revenue outlook for the full year 2026 to be in the range of $207 million to $212 million, raising the midpoint…
Cytek Biosciences Earnings Call Transcript: Q2 2026
Q2 2026 revenue grew 6% year-over-year to $48.1 million, led by strong U.S. and China performance and robust service growth. New product launches and a strategic reorganization support future expansion, while full-year guidance was raised to $207–$212 million.
Cytek Biosciences Quarterly report: Q2 2026
Cytek Biosciences has published its Q2 2026 quarterly earnings report on August 5, 2026.
Cytek Biosciences Slides: Q2 2026
Cytek Biosciences has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 5, 2026.
Cytek Biosciences Earnings release: Q2 2026
Cytek Biosciences released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
Cytek Biosciences Reports Second Quarter 2026 Financial Results
FREMONT, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results ...
Cytek Biosciences to Report Second Quarter 2026 Financial Results on August 5, 2026
FREMONT, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced that it will report financial results for the second quarter...
Cytek® Biosciences Opens New Innovation Center in Bellevue to Advance R&D and Customer Engagement
FREMONT, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Spectral flow cytometry leader Cytek Biosciences, Inc. (Nasdaq: CTKB) today announced the opening of a new innovation center in Bellevue, Washington,...
Cytek Biosciences Transcript: Singular Research’s Las Vegas Invitational Conference
Cytek Biosciences showcased strong global growth, innovative Full Spectrum technology, and a robust recurring revenue model. Recent product launches and a growing installed base position the company for continued outperformance, with margin improvements expected in 2026.
Cytek Biosciences Slides: Singular Research’s Las Vegas Invitational Conference
Cytek Biosciences has posted slides in relation to its latest quarterly earnings report, which was published on June 15, 2026.
Cytek Biosciences to participate at the Singular Research's Las Vegas Invitational Conference
FREMONT, Calif., June 10, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced that the company will be participating in the upco...
Cytek Biosciences Transcript: AGM 2026
The meeting covered director elections, executive compensation approval, and auditor ratification. All proposals passed, and a Q&A session followed. Final voting results will be filed on Form 8-K.
Cytek Biosciences to Unveil Next-Generation Spectral Flow Cytometry Innovations at CYTO 2026
At CYTO 2026, Cytek will showcase its cell analysis solutions, including the public debut of a new 7-laser Cytek Borealis full spectrum flow cytometer.
Cytek Biosciences price target lowered to $4.75 from $5.50 at Stephens
Stephens lowered the firm’s price target on Cytek Biosciences (CTKB) to $4.75 from $5.50 and keeps an Overweight rating on the shares. While revenue was roughly in line and FY26…
Cytek Biosciences price target lowered to $5.50 from $6 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Cytek Biosciences (CTKB) to $5.50 from $6 and keeps an Equal Weight rating on the shares.
Cytek Biosciences Earnings Call Transcript: Q1 2026
Q1 2026 revenue grew 6% year-over-year to $44.1 million, led by strong U.S. instrument sales and double-digit growth in services and reagents. Recurring revenue rose to 35% of total, while net loss widened due to higher operating expenses. Full-year guidance of $205–$212 million was reaffirmed.
Cytek Biosciences Quarterly report: Q1 2026
Cytek Biosciences has published its Q1 2026 quarterly earnings report on May 7, 2026.
Cytek Biosciences Earnings release: Q1 2026
Cytek Biosciences released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Cytek Biosciences Slides: Q1 2026
Cytek Biosciences has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 7, 2026.
Cytek Biosciences Reports First Quarter 2026 Financial Results
FREMONT, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results f...
Cytek Biosciences Proxy statement: Proxy filing
Cytek Biosciences filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
Cytek Biosciences Proxy statement: Proxy filing
Cytek Biosciences filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.